Between 2002 and 2007, travel related cases of Shigella sonnei and S. flexneri in Alberta, Canada were acquired from Central America, the Indian subcontinent and North America. Of this group, resistance to ciprofloxacin and nalidixic acid was identified in isolates from patients who had travelled to the Indian subcontinent. This study provides a Canadian perspective to a growing body of literature linking ciprofloxacin and nalidixic acid resistance to travel to the Indian subcontinent.Shigella is a common cause of diarrheal illness in North America with a rate of 2.0 per 100,000 in Canada 1 and a rate of 3.2 per 100,000 in the United States 23. Imported cases of Shigella infections have been reported in developed countries following travel to a foreign or developing country 45 and may be impacted by factors including socio-economic factors 6, food distribution networks 5 and microbiologic factors 7. Across multiple geographic regions, high rates of antimicrobial resistance to multiple agents (e.g. sulfonamides, tetracycline, chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole) have limited the choices for empiric antimicrobial therapy required to manage Shigella infections and reduce fecal excretion of the bacteria 8910 with descriptions of shifting species dominance and changes in antimicrobial susceptibility 1011. Generally, Shigella flexneri and Shigella sonnei are the dominant species and are heavily impacted by changes in antimicrobial susceptibility 1213.This study identifies the global regions associated with travel-related cases of S. flexneri and S. sonnei in Alberta, Canada and compares antibiotic resistance patterns of these isolates for 2002 to 2007 inclusive.Specimens collected 2002-2007 (inclusive) from S. flexneri and S. sonnei infections in Alberta, Canada were included for study. Data collected at time of specimen submission included: date of specimen collection, outbreak association if present, travel history and antibiogram (data source-ProvLab Information Systems; Communicable Disease Report at Alberta Health and Wellness). Outbreaks were defined by public health officials as ≥ 2 epidemiologically related cases. Each outbreak was assigned a unique incident number. Repeat isolates received within six months of original case infections were excluded. Only one representative case for each outbreak was included, unless the isolates had different antibiotic susceptibility patterns. Based on travel history the origin of an isolate was grouped into corresponding regions and continents. Regions included in the study represented major travel destinations for individuals living in Canada. Domestic exposures were defined as "travel within North America."

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988768PMC
http://dx.doi.org/10.1186/1744-8603-6-20DOI Listing

Publication Analysis

Top Keywords

shigella sonnei
12
2002 2007
12
alberta canada
12
shigella flexneri
8
flexneri alberta
8
cases shigella
8
indian subcontinent
8
north america
8
ciprofloxacin nalidixic
8
nalidixic acid
8

Similar Publications

Unlabelled: Toxin:antitoxin (TA) systems are widespread in bacteria and were first identified as plasmid addiction systems that kill bacteria lacking a TA-encoding plasmid following cell division. TA systems have also been implicated in bacterial persistence and antibiotic tolerance, which can be precursors of antibiotic resistance. Here, we identified a clinical isolate of (CS14) with a remarkably stable pINV virulence plasmid; pINV is usually frequently lost from , but plasmid loss was not detected from CS14.

View Article and Find Full Text PDF

infection poses a significant public health challenge in the developing world. However, lack of a widely available mouse model that replicates human shigellosis creates a major bottleneck to better understanding of disease pathogenesis and development of newer drugs and vaccines. BALB/c mice pre-treated with streptomycin and iron (FeCl) plus desferrioxamine intraperitoneally followed by oral infection with virulent resulted in diarrhea, loss of body weight, bacterial colonization and progressive colitis characterized by disruption of epithelial lining, loss of crypt architecture with goblet cell depletion, increased polymorphonuclear infiltration into the mucosa, submucosal swelling (edema), and raised proinflammatory cytokines and chemokines in the large intestine.

View Article and Find Full Text PDF

Cluster of extensively drug-resistant Shigella sonnei carrying bla in Los Angeles, California, 2023 to 2024.

Am J Infect Control

December 2024

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA. Electronic address:

We describe 3 cases of extensively drug-resistant Shigella sonnei infections among men who have sex with men in Los Angeles, CA. Using whole-genome sequencing, we determined that they are highly genetically related, exhibit similar antimicrobial resistomes, and appear to be distinct from other circulating strains. These cases highlight the rapid expansion of extensively drug-resistant Shigella in the United States and the urgent need for appropriate detection and management.

View Article and Find Full Text PDF

(L.) is an herbaceous medicinal plant belonging to the Polygonaceae family. The plant is distributed in Nepal, India, Japan, China, Russia, and Korea.

View Article and Find Full Text PDF

Shigellosis, a diarrheal disease caused by Shigella species, is a significant public health concern, particularly in developing countries with inadequate sanitation systems. This study aimed to investigate the patterns of antibiotic resistance, ESBL and AmpC genes, integrons, and enterotoxin genes in Shigella species isolated from patients with gastroenteritis in Northeast Iran. This cross-sectional study was conducted between January 2017 and December 2019 at a tertiary care hospital in Northeast Iran.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!